94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Tomasz Sirek1,2*
Katarzyna Król-Jatręga1,2Przemysław Borawski3
Nikola Zmarzły4
Dariusz Boroń4,5,6,7Piotr Ossowski4
Olga Nowotny-Czupryna4Kacper Boroń1Dominika Janiszewska-Bil4Elżbieta Mitka-Krysiak4
Beniamin Oskar Grabarek4,8- 1Department of Plastic Surgery, Faculty of Medicine, Academia of Silesia, Katowice, Poland
- 2Department of Plastic and Reconstructive Surgery, Hospital for Minimally Invasive and Reconstructive Surgery in Bielsko-Biała, Bielsko-Biala, Poland
- 3Independent Researcher, Włocławek, Poland
- 4Department of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland
- 5Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Kraków, Poland
- 6Department of Gynecology and Obstetrics, TOMMED Specjalisci od Zdrowia, Katowice, Poland
- 7University of Economics and Humanities in Warsaw, Warszawa, Poland
- 8Department of Molecular, Biology Gyncentrum Fertility Clinic, Katowice, Poland
By Sirek T, Król-Jatręga K, Borawski P, Zmarzły N, Boroń D, Ossowski P, Nowotny-Czupryna O, Boroń K, Janiszewska-Bil D, Mitka-Krysiak E and Grabarek BO (2025). 14:1515387. doi: 10.3389/fonc.2024.1515387
In the published article, there was an error in Figure 1 as published. The incorrect image was displayed. The corrected Figure 1 and its caption “Venn diagram of genes differentiating breast cancer from the control. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin” appear below.
Figure 1
Figure 1. Venn diagram of genes differentiating breast cancer from the control. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin.
In the published article, there was an error in Figure 2 as published. The incorrect image was displayed. The corrected Figure 2 and its caption “Expression profile of selected genes determined by qRT-PCR. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin” appear below.
Figure 2
Figure 2. Expression profile of selected genes determined by qRT-PCR. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin.
In the published article, there was an error in Figure 3 as published. The incorrect image was displayed. The corrected Figure 3 and its caption “Relationship network for the selected PI3K/AKT/mTOR pathway differentiation genes generated in the STRING database. COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin” appear below.
Figure 3
Figure 3. Relationship network for the selected PI3K/AKT/mTOR pathway differentiation genes generated in the STRING database. COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin.
In the published article, there was an error in Figure 6 as published. The incorrect image was displayed. The corrected Figure 6 and its caption “Overall survival analysis for luminal B HER2+ subtype” appear below.
Figure 6
Figure 6. Overall survival analysis for luminal B HER2+ subtype.
In the published article, there was an error in Figure 7 as published. The incorrect image was displayed. The corrected Figure 7 and its caption “Overall survival analysis for non-luminal HER2+ cancers subtype” appear below.
Figure 7
Figure 7. Overall survival analysis for non-luminal HER2+ cancers subtype.
In the published article, there was an error in Figure 8 as published. The incorrect image was displayed. The corrected Figure 8 and its caption “Overall survival analysis for TNBC subtype” appear below.
Figure 8
Figure 8. Overall survival analysis for TNBC subtype.
In the published article, there was an error. The title of sub-section 3.1 was incorrect.
A correction has been made to Section 3. Results, Sub-section 3.1. This sentence previously stated:
“Microarray profile of histaminergic system-related genes breast cancer samples in comparison with control tissue”
The corrected sentence appears below:
“Microarray profile of PI3K/AKT/mTOR pathway-related genes breast cancer samples in comparison with control tissue”
In the published article, there was an error. The title of sub-section 3.2 was incorrect.
A correction has been made to Section 3. Results, Sub-section 3.2. This sentence previously stated:
“Expression pattern of histaminergic system-related genes in breast cancer samples compared to control tissue analyzed by qRT-PCR”
The corrected sentence appears below:
“Expression pattern of PI3K/AKT/mTOR pathway-related genes in breast cancer samples compared to control tissue analyzed by qRT-PCR”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: breast cancer, miRNA, PI3K/Akt/mTOR pathway, molecular marker, mRNA
Citation: Sirek T, Król-Jatręga K, Borawski P, Zmarzły N, Boroń D, Ossowski P, Nowotny-Czupryna O, Boroń K, Janiszewska-Bil D, Mitka-Krysiak E and Grabarek BO (2025) Corrigendum: Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets. Front. Oncol. 15:1558771. doi: 10.3389/fonc.2025.1558771
Received: 17 February 2025; Accepted: 21 March 2025;
Published: 08 April 2025.
Edited and Reviewed by:
Catalin Marian, Victor Babes University of Medicine and Pharmacy, RomaniaCopyright © 2025 Sirek, Król-Jatręga, Borawski, Zmarzły, Boroń, Ossowski, Nowotny-Czupryna, Boroń, Janiszewska-Bil, Mitka-Krysiak and Grabarek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tomasz Sirek, ZHJ0a2llcmthQGdtYWlsLmNvbQ==